SC
SYRE icon

Stephens Consulting’s Spyre Therapeutics SYRE Stock Holding History

Stephens Consulting’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$323 – 1917
2025
Q1 		$323 Buy
+20
New +$416 ﹤0.01% 1441

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Stephens Consulting's SYRE Position: Q2 2025 in Review

Stephens Consulting sold out of Spyre Therapeutics (SYRE) in Q2 2025, closing a stake of 20 shares — an estimated $323 sold.

Stephens Consulting first reported a position in SYRE in Q1 2025 and held it in 1 quarter. The position peaked at $323 in Q1 2025. 129 funds tracked by Wall St. Rank hold SYRE as of Q2 2025.

  • Stephens Consulting reported no remaining Spyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 20 Spyre Therapeutics shares in Q2 2025, an estimated $323.
  • Stephens Consulting first reported a position in Spyre Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's Spyre Therapeutics position peaked at $323 in Q1 2025.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.